Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Type
Public
HQ
Princeton, US
Founded
2002
Employees
48 (est)

Key People at Advaxis

Daniel J. O’Connor

Daniel J. O’Connor

President, Chief Executive Officer and Director
Thomas J. McKearn

Thomas J. McKearn

Director
Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer
Thomas A. Moore

Thomas A. Moore

Chairman / CEO
Roni A. Appel

Roni A. Appel

Director
Richard Berman

Richard Berman

Director

Advaxis Locations

Princeton, US

Advaxis Metrics

Advaxis Summary

Founding Date

2002

Market capitalization

$329 M

Closing share price

$8.02

Advaxis Market Value History

Advaxis Online Presence

Advaxis Company Life

You may also be interested in